BACKGROUND AND OBJECTIVES: CD4+ T helper cells are an integral part of effective immune responses against various @entity5 ; however in @entity5 -bearing @entity1 they are frequently functionally unresponsive. T helper cells of @entity1 with @entity1860 ( @entity1860 ), analyzed as part of mononuclear cell fractions, show a loss of signaling molecules, a compromised @entity1198 cytokine production and a shift towards a non-productive Th2 state. The underlying mechanism is unknown and may involve @entity784 as well as indirect effects mediated by @entity1778 or antigen-presenting cells. The purpose of the present study was to analyze the intrinsic cytokine-producing capacity of purified @entity1860 helper cells in the absence of other cell types. DESIGN AND METHODS: Untouched CD4+ T cells with a purity of more than 90% were isolated from 10 @entity1 with Ph+ chronic phase @entity1860 on maintenance treatment with @entity1862 . The cells were isolated by density gradient centrifugation followed by immunomagnetic @entity1778 and accessory cells. The ex vivo cytokine-producing capacity of @entity1860 helper cells in response to polyclonal stimulation with anti-CD3 and anti- @entity1361 was then compared to that of cells purified from matched healthy volunteers. RESULTS: T helper cells purified from @entity1860 @entity1 produced comparable amounts of the @entity1198 cytokines interleukin (IL)-2 and interferon (IFN)-g as cells purified from healthy volunteers. Likewise, no difference between @entity1860 and control T helper cells was found with respect to the Th2 cytokines, @entity3646 and @entity4047 , as well as the immunomodulatory cytokine, @entity688 . INTERPRETATION AND CONCLUSIONS: In the @entity1778 and accessory cells, the intrinsic cytokine-producing capacity of @entity1860 helper cells is normal. A Th2 shift was not detected, and the predominant presence of an @entity688 -producing, immunosuppressive T helper cell subset could be excluded.

Normal intrinsic XXXX /Th2 balance in @entity1 with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4047 :: ('3596', 'Gene') :: ['IL-13'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies'] @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea'] @entity784 :: ('MESH:D016399', 'Disease') :: ['intrinsic T cell defects'] @entity1198 :: ('51497', 'Gene') :: ['Th1'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['absence of leukemia', 'depletion of leukemia', 'leukemia'] @entity3646 :: ('3565', 'Gene') :: ['IL-4'] @entity688 :: ('3586', 'Gene') :: ['IL-10'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia', 'CML T'] @entity1361 :: ('940', 'Gene') :: ['CD28']
@entity1198 :: (51497,Gene) :: ['Th1']
